RESUMO
Our experience of kalumide (bikalutamide) administration in patients with prostatic cancer agrees with the data of other investigators on a good effect of the drug on quality of life of patients with prostatic cancer.
Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos Hormonais/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Neoplasias da Próstata/tratamento farmacológico , Qualidade de Vida , Adenocarcinoma/mortalidade , Adenocarcinoma/secundário , Idoso , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Hormonais/efeitos adversos , Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/secundário , Intervalo Livre de Doença , Humanos , Avaliação de Estado de Karnofsky , Masculino , Neoplasias Hormônio-Dependentes/mortalidade , Neoplasias Hormônio-Dependentes/patologia , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/patologiaRESUMO
The efficacy of the drug cernilton was studied in patients with prostatic adenoma (PA) and chronic bacterial prostatitis (CBP). One group and two subgroups of patients were studied: 31 men with PA received cernilton for 3 months (group 1); 32 patients with CBP received antibacterial treatment (for 8 months) and cernilton for 3 months (group IIa); 30 CBP patients received standard antibiotic treatment for 2 months maximally (group IIb). All the patients were examined before the treatment and 3 months later. According to IPSS, patients of group 1 showed a significant (p < 0.001) regress of low urinary tract symptoms and improvement of quality of life. PSA in the serum lowered by 21.2%. Qmax significantly increased (p < 0.001), Vprost and Vres diminished. According to the scale NIH-CPSI, relief of pain, dysuria was greater, quality of life improved more in patients of group IIa than in group IIb (p < 0.05). The same trend was in the values Qmax, Vres and Vprost. Thus, it is evident that cernilton is effective in monotherapy of PA and combined treatment of CBP.
